Pantoloc · DIN 02229453 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Pantoloc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Pantoloc · DIN 02229453
Manufacturer: Nycomed Canada Inc.; listing date 1997-08-28
Health Canada: Marketed since 2013-01-09 · brand PANTOLOC · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Takeda canada inc · schedule Prescription
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02229453)
Source record
DIN 02229453: Pantoloc
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id NYC
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.0803; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02229453
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47339
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: not checked (no credentials)